NCT04823715CompletedNot Applicable
Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison
Hospices Civils de Lyon1 site in 1 country163 target enrollmentStarted: October 15, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 163
- Locations
- 1
- Primary Endpoint
- Disease-free survival of the patient after start of treatment
Study Overview
Brief Summary
Patients with non-metastatic unresectable hepatocellular carcinoma
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥18 years of age
- •Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASL-AASLD) in cirrhotic patients
- •Child-Pugh class A
- •Absence of truncular or lobar portal vein invasion, or suprahepatic vein invasion
Exclusion Criteria
- •Uncontrolled replication of hepatitis B virus
- •Transplanted liver
- •Previous abdominal irradiation
- •Previous treatment of HCC with systemic therapy, or with surgical resection in the 2 previous years
- •Metastatic illness
Outcomes
Primary Outcomes
Disease-free survival of the patient after start of treatment
Time Frame: Within 10 years after the treatment (surgical resection or TACE)
Disease-Free Survival (DFS) defined as the time (in months) between the treatment (surgical resection or TACE) and the diagnostic of local, locoregional or distant recurrence, or date of death from any cause; patients who are alive or lost to follow-up at the time of the analysis will be censored on the last follow-up date; patients who have received a liver transplant for non-carcinologic reason will be censored on the date of transplantation.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT06232759Guangxi Medical University56
Terminated
Phase 2
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaLiver NeoplasmsNCT02470533Erasmus Medical Center100
Completed
Phase 2
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +AxitinibHepatocellular CarcinomaNCT01352728Chinese University of Hong Kong50
Recruiting
Not Applicable
TACE-HAIC vs. HAIC for Potentially Resectable HCCPotentially ResectionHepatocellular CarcinomaNCT03591705Sun Yat-sen University240
Recruiting
Phase 2
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialHepatocellular CarcinomaNCT05751343Sun Yat-sen University55